fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Immunotherapy – where are we now?

Written by | 11 Nov 2019

Immunotherapy now has an established place in treatment of non-small cell lung cancer but many questions remain such as the role of tumour mutational burden as a biomarker… read more.

Mesothelioma trials update

Written by | 10 Jul 2019

Dr Popat gives an update of the ongoing studies in mesothelioma in the UK

UK impact of trial data

Written by | 8 Jul 2019

Dr Fiona McDonald (London, UK) discusses radical treatment for oligo metastatic NSCLC and if it should be the standard of care and Professor James Spicer (London, UK), the session Chair,  gives… read more.

Translational oncology: Tumour mutational burden and exploitation of DNA repair

Written by | 5 Jul 2019

Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.

PACIFIC and beyond – the promise of immunotherapy

Written by | 10 May 2019

Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).

Integrating CAR T-Cell therapy into the treatment of myeloma

Written by | 7 May 2019

Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.

WCLC 2018: Variety of approaches can work in oligometastatic disease

Written by | 17 Oct 2018

Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.

ASCO 2018: Choices for front-line NSCLC

Written by | 20 Aug 2018

With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…

ASCO 2018: Hot topics in lung cancer

Written by | 20 Aug 2018

Hot topics in lung cancer – interviews from ASCO 2018.

ASCO Highlights

Written by | 20 Aug 2018

June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

BSH 2018: Personalised cancer vaccines and cellular therapy: changing the treatment paradigm for haematological malignancies

Written by | 11 May 2018

Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.